Transfusion of autologous late-outgrowth endothelial cells (OECs) is a promising treatment for restenosis after revascularization. Preparing cells by in vitro amplification is a key step to implement the therapy. This study aimed to demonstrate that bilobalide, a terpenoid, enhances the OEC amplification. Human-, rabbit-and rat 
| INTRODUCTION
Late-outgrowth endothelial cells (OECs) also known as bone marrow (BM)-derived ECs are a subtype of endothelial progenitor cells. OECs exist in many organs but are rare anywhere. [1] [2] [3] It is difficult to selectively mobilize sufficient OECs to the circulating blood and the diseased organs. We and other research groups have demonstrated that OECs directly participate in the re-endothelialization and by a paracrine pathway inhibit the migration and proliferation of vascular smooth muscle cells; transfusion of sufficient OECs soon after vascular injury may reduce neointima formation, [4] [5] [6] opening a new way to inhibit the restenosis process after revascularization procedures such as percutaneous balloon angioplasty, stent implantation or atherectomy. In the forementioned three studies, we transfused autologous OECs that were prepared by in vitro amplification to the experimental rabbits while the two other research groups delivered allogeneic OECs to the immunodeficient mice. Allogeneic OECs fails to prevent intimal hyperplasia in immunity-intact rats. 7 Expanding OECs is a key step to implement the autologous-OECstherapy. However, as we know, all the current expansion methods [1] [2] [3] [4] [5] [6] [7] [8] have low efficiencies, and getting seed OECs demands a large amount of peripheral blood (PB) or BM. Hence, it is useful to enhance the OEC expansion. As OECs have endothelial nitric oxide synthase (eNOS) and can proliferate whereas the early-outgrowth endothelial progenitor cells lack eNOS and do not proliferate, 9, 10 we hypothesized that nitric oxide is involved in OEC proliferation, and additives that can modulate the eNOS/nitric oxide pathway may accelerate the OEC amplification.
Bilobalide, a sesquiterpenoid having a 15-carbon skeleton (Fig- ure S1), is originally found in Ginkgo biloba leaves. Ginkgo biloba leaf is widely used in traditional Chinese medicine, and its standardized extract EGb 761 has been used worldwide because of multifaceted pharmacological benefits. 11 Bilobalide accounts for 2.6%-3.2% of EGb 761 and contributes to EGb 761's vasodilating effect. 12 Although there is no report of using bilobalide alone in clinic, animal experiments have attested that bilobalide increases cerebral blood flow 13 and decreases arterial blood pressure, especially the diastolic pressure. 14, 15 An in vitro study using aorta ring strips reveals that the vasorelaxation of bilobalide could be reduced significantly by NOS inhibitors. 16 Bilobalide decreases the activity or expression of iNOS in some non-vascular cells or tissues. [17] [18] [19] Our second hypothesis was that bilobalide modulates eNOS/nitric oxide pathway, promoting the OEC proliferation.
This article reports our verification of the hypotheses. We find that nitric oxide plays a partial role in OEC proliferation and migration; bilobalide promotes eNOS activation and superoxide scavenging to increase intracellular nitric oxide, enhancing the OEC expansion; bilobalide-based OECs are active in vivo.
| MATERIALS AND METHODS

| Ethics
The procedures of the study received ethics approval from the Ethi- 
| Amplification of OECs
Obtaining rabbit PB and BM and from them isolating mononuclear cells (MNCs) refer to our previous report. 4 Human PB MNCs were isolated in the same way. Rat BM was harvested from the femurs and tibias of male Sprague-Dawley rats (250-280 g, supplied by the Laboratory Animal Center of Xi'an Jiaotong University) killed with inhalation of CO 2 .
MNCs were plated on 100-mm culture dishes that had been coated with human fibronectin (for PB OECs) or rat collagen type I (for BM OECs), and were cultured for over 2 weeks in endothelial growth medium-2 (EGM-2, Lonza-BioWhittaker, Walkersville, MD, USA) at 37°C, letting the included OECs increased while other cell types disappeared.
The medium was changed every other day. Cells were subcultured when they approached 90% confluence. For bilobalide groups, bilobalide (0.1-10 lmol/L; Sigma-Aldrich, St Louis, MO, USA) was added into EGM-2. Bilobalide was dissolved in DMSO and diluted with PBS beforehand. The final concentration of DMSO was below 0.05% (v/v).
| OEC characterizing
The LDL uptake and agglutinin binding were indicated by 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine-labelled acetylated LDL (Dil-acLDL, Molecular Probes, Eugene, OR, USA) and FITC-conjugated lectin from Ulex europaeus (FITC-lectin, Sigma-Aldrich), respectively. 4 The existences of CD 144, CD14 and CD45 were determined with FACS. 4 FITC-conjugated rabbit polyclonal antibody (pAb) against human CD144 and mouse monoclonal antibody (mAb) against human CD14 were purchased from GenWay (San Diego, CA, USA), and FITC-mAb against rabbit CD45 from Research Diagnostics (Scottsdale, AZ, USA). The existences of eNOS and caveolin-1 were confirmed with immunofluorescence staining. Two 1 cm 2 -areas of cells fixed by paraformaldehyde (2%) were crayon-circled, one was for eNOS and the other was for caveolin-1. After permeabilization by 5% goat serum, 0.1% Triton X-100 and 10 mmol/L glycine, the circled cells were incubated for 1 hour in 10% goat serum at room tempera- Transluminal mechanical injury of the femoral artery was performed according to the literature reports. 5, 19, 20 Briefly, the left femoral artery and a branch between the rectus femoris and vastus medialis muscles were exposed and looped proximally and distally with silk suture. Transverse arteriotomy was performed in the exposed muscular branch artery, through which a straight spring wire (0.38 mm diameter) was inserted into the femoral artery. The wire was slowly push-and-pulled for 4 times and left in place for 1 minute to denude and dilate the artery, then was removed and the suture looped at the proximal portion of the muscular branch artery was secured.
Blood flow in the femoral artery was restored by releasing the sutures placed in the proximal and distal femoral portions.
The model mice were divided into 5 groups: PBS, OECs, bilobalide negative) via FACS. Femoral arteries were sampled at day 28 to make 5-lm thick frozen sections and H&E-stained. Indices of the neointima formation were analysed with the image analysis system (Q550CW, Leica) as our previous report. 4 Most importantly, the internal elastic lamina was set as the boundary between intima and media. Related details refer to our previous report. For N G -nitro-L-arginine methyl ester (L-NAME) groups, L-NAME at 37°C followed by elimination of supernatant and washing twice.
To each well was added 200 lL DMSO, followed by shaking for 10 minutes, and detection of the OD by a microplate spectrophotometer (Bio Rad) set to a wavelength of 490 nm. 
| BrdU assay
| Migration assay
The modified Boyden chamber assay 22 was used. Briefly, transwell inserts (Costar Transwell membrane, 6.5 mm diameter, 12.0 lm pore size) were placed in 24-well dishes. Rabbit PB OECs were plated on the upper wells (5 9 10 4 cells/well) to culture for 24 hours in EBM-2 containing FBS (5%) and stromal cell-derived factor-1a (SDF-1a, 100 ng/ mL; Sigma-Aldrich). Adding bilobalide and L-NAME into the media of related groups refers to the above description. Cells that migrated to the underside of the membrane were Hoechst-stained for counting. Although there is no difference in the intima area and media area between the OECs and OECs + bilobalide groups, the lumen area of OECs + bilobalide group is larger than that of OECs alone group, conforming bilobalide's vasodilating effect.
| Western blotting
EGM-2 to expand the included OECs. Four weeks later, as shown indid not alter the OEC characteristics. For example, the PB OECs that were amplified in the presence of 10 lmol
| Bilobalide promotes OEC proliferation and increases intracellular nitric oxide level
BrdU incorporation assay and cell viability measurement by MTT assay, respectively, are often used direct and indirect methods for attesting cell proliferation. In this study, MTT assay showed that
HUVECs and rabbit PB OECs increased their numbers to 
| Nitric oxide mediates bilobalide-promoting OEC proliferation
MTT assay showed that pre-treatments by L-NAME (5 lmol/L), a NOS inhibitor, and PD98059 (10 lmol/L), a MAPK kinase inhibitor, both slow FBS-and VEGF-induced proliferations of rabbit PB OECs, and abolish bilobalide (1-10 lmol/L)'s increase effect on the proliferations ( Figure 4A,B) . Another experiment using rat BM OECs showed that VEGF-induced ERK1/2 phosphorylation, more P-ERK1/2 was detected at 5 minutes than that at 10 minutes; bilobalide (1 lmol/L) did not affect the P-ERK1/2 at 5 minutes, but increased that at 10 minutes; L-NAME pre-treatment did not alter the VEGF-based P-ERK1/2, but abolished the increase in bilobalide of P-ERK1/2 ( Figure 4C ).
F I G U R E 4
Effects of nitric oxide synthesis inhibition on bilobalide-promoting OEC's proliferation and ERK1/2 activation. Rabbit PB OECs were treated with L-NAME (5 lmol/L) or PD98059 (10 lmol/L) for 30 min before exposed to FBS (A) or VEGF (B) and tested viability by MTT assay. Rat BM OECs were pre-treated with L-NAME then exposed to VEGF and detected P-ERK1/2 at the indicated time-points (C). In bilobalide groups, bilobalide (1 lmol/L) was added at the same time as FBS (10%) or VEGF (100 ng/mL). (A,B) n = 4 per group. *P < .05 and **P < .01 vs L-NAME (À) + PD98059 (À) + bilobalide (À);
vs L-NAME (À) + PD98059 (À) + bilobalide (+). (C)
Upper, representative Western blotting bands; Lower, statistics: n = 4 per group. *P < .01 vs 0 min;
vs L-NAME (À) + bilobalide (+)
F I G U R E 5 Effects of eNOS-and iNOS knock-downs on nitric oxide level in OECs. Rat BM OECs were decreased eNOS-and iNOS expression by the respective siRNA. Non-stimulation means cells are in EBM-2 without serum, VEGF (100 ng/mL) and bilobalide (1 lmol/ L). n = 3 per group. **P < .01 vs control siRNA
| Bilobalide promotes OEC eNOS activation
Late-outgrowth endothelial cells constitutively express eNOS and iNOS. 10 We used siRNA to decrease rat BM OECs expressing eNOS and iNOS; the decrease rates were 62.4% and 67.2%, respectively.
The eNOS knock-down decreased the nitric oxide level in the quies- 
| Bilobalide promotes OEC migration
As shown in Figure 9 , some of the OECs that had been plated on the upper well of the transwell insert migrated to the underside of transwell membrane within 24 hours of incubation. L-NAME shows that intracellular P-ERK1/2 as well as nitric oxide increases at 5 minutes after OECs exposure to VEGF, and pre-treatment by L-NAME does not abolish the increment of P-ERK1/2, suggesting up to this time the nitric oxide production and ERK1/2 activation are mutually independent. Bilobalide increases the P-ERK1/2 at 10 minutes, which is abolished by the L-NAME pre-treatment, suggesting nitric oxide mediates bilobalide-promoting ERK1/2 activation. The case is similar to previous reports that eNOS/NO pathway partly mediates VEGF-, PGE 2 -, and Korean red ginseng water extract evoking ERK1/2 activation in ECs. 27, 30, 31 Late-outgrowth endothelial cells have eNOS and iNOS. 10 Bilobalide decreases iNOS expression in some cell types. [17] [18] [19] The effect of bilobalide on eNOS remains unclear so far. Our present data excluded bilobalide increasing OEC's eNOS-and iNOS expression.
The eNOS is regulated activity by phosphorylation at multiple sites. F I G U R E 9 Effect of bilobalide on migration of rabbit PB OECs. The modified Boyden chamber assay was used. Additions of bilobalide and L-NAME refer to Figure 3 . For each sample, migrated cells in 3 randomly chosen visual fields (9100) were counted and averaged. n = 6-7 per group. *P < .05 and **P < .01 vs 0 lmol/L bilobalide; #P < .01 vs none L-NAME scavenges ROS to reduce nitric oxide depletion by O 2 À • in activated OECs.
In summary, the present study demonstrates that nitric oxide plays a role in OEC proliferation and migration; bilobalide increases nitric oxide production and prolongs the lifespan of available nitric oxide to enhance OEC growth. The findings may facilitate in vitro expansion of OECs, which may simplify the preparation of OECs for the autologous-OECs-transfusion therapy.
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